(1) Background: Endometrial carcinoma (EC) classified as no specific molecular profile (NSMP) represents a heterogeneous group with variable prognoses. This retrospective, single-center study aims to further stratify NSMP ECs to tailor treatment strategies and improve outcomes. (2) Methods: From 2020 to 2023, we collected data on 51 patients diagnosed with NSMP EC following the introduction of molecular profiling at our institution. Patients were retrospectively analyzed for estrogen receptor (ER) status, histotype, and grade to identify potential prognostic subgroups. (3) Results: Our analysis identified two distinct subgroups within NSMP EC: low-risk and high-risk, based on ER status, histotype, and grade. The low-risk NSMP group demonstrated significantly better survival outcomes compared to the high-risk group. With a median follow-up time of 16 moths (IQR 13.0–29.7), the disease-free survival (DFS) and overall survival (OS) for the low-risk group were 100%. For the high-risk group, the DFS and OS were 71.4% and 78.6%, respectively, which showed a statistically significantly difference (Log-Rank Mantel-Cox < 0.001). In the high-risk group, four patients experienced recurrence, and three of these patients died. (4) Conclusions: Stratifying NSMP EC into low-risk and high-risk categories based on ER status, histotype, and grade can lead to more accurate prognostic assessments. In time, it may require tailored adjuvant therapies and a personalized treatment.
(1) 背景：被归类为无特定分子谱（NSMP）的子宫内膜癌（EC）是一个预后存在差异的异质性群体。这项回顾性、单中心研究旨在进一步对NSMP EC进行分层，以制定个体化治疗策略并改善预后。(2) 方法：自2020年至2023年，我们收集了本机构引入分子分型后诊断为NSMP EC的51例患者数据。回顾性分析患者的雌激素受体（ER）状态、组织学类型和分级，以识别潜在的预后亚组。(3) 结果：根据ER状态、组织学类型和分级，我们在NSMP EC中识别出两个不同的亚组：低风险组和高风险组。与高风险组相比，低风险NSMP组显示出显著更优的生存结局。中位随访时间为16个月（四分位距13.0–29.7），低风险组的无病生存率（DFS）和总生存率（OS）均为100%。高风险组的DFS和OS分别为71.4%和78.6%，两组间差异具有统计学显著性（Log-Rank Mantel-Cox < 0.001）。高风险组中有4例患者出现复发，其中3例死亡。(4) 结论：基于ER状态、组织学类型和分级将NSMP EC分为低风险和高风险类别，可以实现更准确的预后评估。未来，这可能有助于制定个体化的辅助治疗方案，实现精准治疗。
肿瘤(癌症)患者之家